Biogen Inc.
General ticker "BIIB" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $20.2B (TTM average)
Biogen Inc. follows the US Stock Market performance with the rate: 54.8%.
Estimated limits based on current volatility of 1.5%: low 182.87$, high 188.28$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Total employees count: 7605 as of 2024
- US accounted for 1.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Climate change and natural disasters, Supply chain disruptions, Economic downturns and volatility, Regulatory and compliance, Manufacturing disruptions
- Price in estimated range
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [127.41$, 206.25$]
- 2025-12-31 to 2026-12-31 estimated range: [139.27$, 219.22$]
Financial Metrics affecting the BIIB estimates:
- Negative: with PPE of 9.1 at the end of fiscal year the price was high
- Positive: Operating cash flow per share per price, % of 13.21 > 12.96
- Positive: Operating profit margin, % of 25.74 > 18.38
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 5.50
- Positive: Interest expense per share per price, % of 1.15 <= 3.28
- Positive: Inventory ratio change, % of -0.17 <= 0
- Positive: 42.68 < Shareholder equity ratio, % of 59.60 <= 64.29
- Positive: Industry operating profit margin (median), % of 21.15 > 9.59
- Negative: Industry operating cash flow per share per price (median), % of 8.11 <= 10.29
Short-term BIIB quotes
Relationship graph
Long-term BIIB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $10,173.40MM | $9,835.60MM | $9,675.90MM |
| Operating Expenses | $7,284.30MM | $7,738.30MM | $7,185.60MM |
| Operating Income | $2,889.10MM | $2,097.30MM | $2,490.30MM |
| Non-Operating Income | $705.30MM | $-800.50MM | $-584.30MM |
| Interest Expense | $246.60MM | $246.90MM | $250.30MM |
| R&D Expense | $2,597.00MM | $2,702.60MM | $2,488.50MM |
| Income(Loss) | $3,594.40MM | $1,296.80MM | $1,906.00MM |
| Taxes | $632.80MM | $135.30MM | $273.80MM |
| Other Income(Loss) | $2.60MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $3,046.90MM | $1,161.10MM | $1,632.20MM |
| Stockholders Equity | $13,397.90MM | $14,799.40MM | $16,716.00MM |
| Inventory | $1,344.40MM | $2,527.40MM | $2,460.50MM |
| Assets | $24,554.10MM | $26,844.80MM | $28,049.30MM |
| Operating Cash Flow | $1,384.30MM | $1,547.20MM | $2,875.50MM |
| Capital expenditure | $240.30MM | $311.40MM | $359.80MM |
| Investing Cash Flow | $1,589.00MM | $-4,088.70MM | $-799.20MM |
| Financing Cash Flow | $-1,759.70MM | $137.00MM | $-683.50MM |
| Earnings Per Share** | $20.97 | $8.02 | $11.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.